Literature DB >> 3029219

Angiotensin converting enzyme (ACE), characterization by 125I-MK351A binding studies of plasma and tissue ACE during variation of salt status in the rat.

B Jackson, R Cubela, C Johnston.   

Abstract

Angiotensin converting enzyme (ACE) was measured in rat plasma and tissues by analysis of the binding of the radio-inhibitor 125I-MK351A, a tyrosyl derivative of enalaprilic acid. Labelled 125I-MK351A bound to plasma and tissue ACE preparations and was displaced in a concentration-related manner by MK351A. Scatchard analysis yielded a single line from which MK351A binding sites/mg protein and MK351A dissociation constant were calculated. Tissue and plasma ACE from Sprague Dawley rats was studied over a wide range of sodium intakes (low salt, 0.026 +/- 0.012 mmol/24 h; normal salt, 0.58 +/- 0.09 mmol/24 h; and high salt, 10.4 +/- 1.3 mmol/24 h) and during high salt and DOCA treatment. Across the range of sodium states studied there were no consistent changes in plasma, lung, aorta, brain, epididymis or kidney MK351A binding sites/mg protein, or equilibrium dissociation constant. Calculated MK351A binding sites (nmol/mg protein) were 1.64 +/- 0.14 in lung, 0.47 +/- 0.04 in aorta, 0.44 +/- 0.05 in epididymis, 0.18 +/- 0.01 in brain and 0.053 +/- 0.004 in kidney preparations (n = 24 in each group) reflecting reported ACE enzymatic activity in these tissues. Equilibrium dissociation constant KD was uniform within each tissue, but varied between organs. The KD (mol/l X 10(-12)) was 50 +/- 2 in aorta, 57 +/- 2 in lung, 58 +/- 2 in epididymis, 61 +/- 3 in brain, 62 +/- 2 in plasma and 84 +/- 3 in kidney (n = 24 in each group).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3029219     DOI: 10.1097/00004872-198612000-00011

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

Review 1.  Cardiac molecular imaging to track left ventricular remodeling in heart failure.

Authors:  Jamshid Shirani; Amitoj Singh; Sahil Agrawal; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2016-08-01       Impact factor: 5.952

Review 2.  Biochemistry and pharmacology of the renin-angiotensin system.

Authors:  C I Johnston
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Family physician hospital privileges. New approach.

Authors:  B Hennen
Journal:  Can Fam Physician       Date:  1995-03       Impact factor: 3.275

Review 4.  Innocent heart murmurs in children. Taking a diagnostic approach.

Authors:  N R Saunders
Journal:  Can Fam Physician       Date:  1995-09       Impact factor: 3.275

5.  Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.

Authors:  B Fabris; H Yamada; R Cubela; B Jackson; F A Mendelsohn; C I Johnston
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

Review 6.  Novel molecular angiotensin converting enzyme and angiotensin receptor imaging techniques.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

7.  Angiotensin converting enzyme binding sites in human heart and lung: comparison with rat tissues.

Authors:  T Vago; M Bevilacqua; F Conci; G Baldi; E Ongini; E Chebat; A Monopoli; G Norbiato
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

8.  Rural home care of a technology-dependent infant.

Authors:  J E Clarke
Journal:  Can Fam Physician       Date:  1995-06       Impact factor: 3.275

9.  Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor.

Authors:  S E Telford; A I Smith; R A Lew; R B Perich; A C Madden; R G Evans
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

10.  Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.

Authors:  David G Levitt; Rik C Schoemaker
Journal:  BMC Clin Pharmacol       Date:  2006-01-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.